Presentation Title Goes Here and Second Line Here

TM11 CALYSTA Energy Biology provides a real opportunity to produce high-value chemicals from novel feedstocks Calysta is a first mover in bioconversion of methane, enabling preferred partners to dramatically reduce feedstock costs Best-in-class technology, experienced management team, solid financial backing, extensive intellectual property, proven

  Title, Presentation, Goes, Here, Presentation title goes here

Re: Medicare Prescription Drug Benefit Manual – …

infusion therapy are in place before dispensing home infusion drugs.”2 This requires a home infusion pharmacy to provide the Part D plan with assurances that

  Manual, Prescription, Drug, Benefits, Medicare, Medicare prescription drug benefit manual

Re: Medicare Prescription Drug Benefit Manual – …

September 26, 2006 BY ELECTRONIC DELIVERY Cynthia Tudor, Ph.D. Director, Medicare Drug Benefit Group Centers for Medicare & Medicaid Services

  Manual, Prescription, Drug, Benefits, Prescription drug benefit manual, Drug benefit

Consumer Products Made with Industrial …

Toxic chemicals, such as aniline, used in a nine step chemical synthesis process (hazardous waste generated)

  Chemical

Emerging Therapeutic Company Investment and Deal Trends

• Venture Capital: 2015 was the best year on record for US venture capital, with just under $7 billion raised. Funding Funding of immuno-oncology and neurodegenerative disease companies helped drive …

  Company, Venture, Capital, Investment, Emerging, Therapeutic, Venture capital, Emerging therapeutic company investment and

Valuation and Deal Structuring

Valuation and Deal Structuring BIO’s Advanced Business Development Course June 2015 Prepared for: Joe Dillon President Bringing money to medicine© ℠ DILLONCAPITAL S T R A T E G I E S

  Deal, Structuring, Valuation, Valuation and deal structuring

Emerging Clinical Therapeutic Company Development ... - BIO

2 | BIO Industry Analysis About BIO BIO is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and

  Bio bio

Clinical Development Success Rates 2006-2015 - BIO

About BIO BIO is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.

  Development, Clinical, Success, Bio bio, Clinical development success

Valuation and Deal Structuring

Big Pharma –1987 to 1996. Business Development, Evaluation and Analysis, R&D Portfolio Strategy, Long-range Planning, Forecasting and Finance. Education –BBA in Finance, MBA in International Finance and several years teaching at the graduate level. Focus: Partnering/BD, strategic planning, deal strategy, deal

  Deal

Clinical Development Success Rates 2006-2015

the most comprehensive analysis yet of biopharmaceutical R&D success. ... Only company-sponsored, FDA registration-enabling development programs were considered; investigator-sponsored studies ... This is also the point in development where industry must decide whether to pursue the large, expensive Phase III studies and may decide to terminate ...

  Industry, Sponsored, Biopharmaceutical

A global perspective on the floating offshore wind industry

Who we are •Mission: Develop new offshore wind energy projects globally by combining outstanding global industry knowledge with local development expertise •Team: one of the most experienced teams in floating wind development globally, from various backgrounds and covering all the floating supply chain •Business approach: Agile, rigorous, passionate, lean, ethical